fashion -WSS

fashion

author：entertainment 2025-09-30 16:23:22 - browse：5

As a new class of diabetes and obesity medications has soared in popularity, so have the online outlets built to get them in the hands of patients. A new analysis of claims data from Trilliant Health suggests that collectively, telehealth companies — in particular, cash-pay options that market directly to consumers — could account for many of the patients with insurance claims for GLP-1 prescriptions in 2022.

Direct-to-consumer telehealth companies have offered an easier on-ramp for many patients to access prescriptions for a variety of conditions. And since the first GLP-1s were approved for obesity — promising up to 15% weight loss — many of those companies have capitalized on the approvals and surging demand to launch new weight loss businesses. Companies including Calibrate and Ro claim to have reached tens and hundreds of thousands of patients with their weight loss medication programs.

Collectively, their reach may be even larger. The Trilliant Health analysis, conducted on behalf of STAT, offers an early glimpse of the foothold those businesses have gained in GLP-1 prescribing. In a nationwide claims database of more than 300 million patients using both commercial and federal insurance, Trilliant Health found about 3.6 million people with a prescription claim for a GLP-1 — semaglutide, tirzepatide, or injectable liraglutide without insulin — in 2022. To determine where each patient may have gotten those prescriptions, they looked for a medical visit claim within three days of a prescription claim for a GLP-1 — the visit where the script was likely written. But they only found a matching visit for 53% of patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Pancreatic cancer early detection could be helped by AI

WSS

More doctors should go into startup world

Pancreatic cancer early detection could be helped by AI

Humana’s losses in Medicare Advantage tank its stock

AstraZeneca CEO says participant had neurological symptoms, could be discharged today

Removing probiotics from the NICU could threaten preemies' health

FTC sues over Novant Health acquisition of two N.C. hospitals

entertainment

fashion

Wikipedia

United colonoscopy coverage change 'may cost lives,' doctors say

10 million people disenrolled from Medicaid over past six months

Hepatitis C has a cure — but many Americans still lack access to it

Medicare drug price negotiation legal challenge met with skepticism

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Humana’s losses in Medicare Advantage tank its stock

Psychedelics group wrestles with new pharma identity

Readout Newsletter: The latest on Novavax, Merck, Bluebird

After affirmative action ruling, medical educators look to 'holistic review'

10 million people disenrolled from Medicaid over past six months

explore

Merck, Johnson & Johnson CEOs will testify on high drug prices

White House pharmacy plagued with problems, investigation finds

A clever new way to fix Medicaid and graduate medical education

Why Medicare shouldn’t cover every FDA

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Abortion clinic in Cancun will cater to Americans

focus

focus

hotspot

hotspot